| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 无锡祥生医疗科技股份有限公司由国家级超声专家莫善珏先生于1996年创立，28年来始终专注超声领域，致力于通过前沿超声技术的研发和创新来改善医疗，为人类健康创造价值。目前，公司拥有45项主要核心技术，涵盖全身应用超声、专科超声、智能超声领域以及探头核心部件，已获得650余项海内外知识产权（截止至2023年底）。自主研发、制造的产品远销国内外100多个国家和地区，受到市场广泛认可。2019年12月3日祥生医疗成功登陆科创板（股票代码：688358），成为中国科创板的超声第一股。 公司始终坚持以解决临床痛点为己任、深耕专科领域，在专科化、便携小型化、智能化三个方面形成显著的差异化竞争优势，作为民族医疗器械企业，祥生医疗积极践行强化国家战略科技力量要求，打造具有国际影响力的民族品牌，矢志成为全球超声发展趋势的领跑者。 祥生医疗在中美两地设有研发中心，公司不仅是国家知识产权优势企业、国家级博士后科研工作站、高新技术企业和江苏省工程技术研究中心，多年来作为牵头单位还先后承担了“十二五”国家科技支撑计划—“专用超声诊断探头部件及系统研发”课题、“十三五”国家重点研发计划—“乳腺三维超声容积成像系统及面阵探头的研制”项目的研发工作，三次承担了科技部“国家火炬计划项目”的科研工作，两次承担了“江苏省科技成果转化专项资金”项目，并承担了“江苏省自然科学基金青年基金项目”的科研任务，充分体现了祥生医疗在技术方面的研究开发能力。同时，联合多个科研院所及医疗机构进行技术攻关，取得世界级成果，成为中国超声的国家科研担当。 | ||||||||||||||||||||||||
| Main Business | 超声医学影像设备研发、制造和销售。 | ||||||||||||||||||||||||
| Legal Representative | 莫若理 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 周峰 | ||||||||||||||||||||||||
| Solicitors | 上海市通力律师事务所 | ||||||||||||||||||||||||
| Auditors | 容诚会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0510-85271380 | ||||||||||||||||||||||||
| Fax No | 0510-85271360 | ||||||||||||||||||||||||
| Website | www.chison.com | ||||||||||||||||||||||||
| info@chison.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 03/12/2019 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.330 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.800 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 12.210 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.698B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |